A renaissance for SRC
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that SRC activation may also be a dominant feature in CRC, which is supported by the observation that SRC activation was documented in > 80% of CRC [17].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“In response signaling from a variety of RTKs (including EGFR, HER2, HER4, PDGFR, VEGFR, FGFR4, GPCR, C-MET, IL-4/IL13/IL-13Rα2, IL-6ST/IL-6R/IL-11R), SRC has been reported to mediate diverse cell signaling pathways including RAS/MAPK (proliferation), PI3K/AKT (survival), FAK (adhesion/migration/EMT), and STAT3 (angiogenesis) [17, 49, 50].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [39]
In the citing paper
“The c-src is a non-receptor protein tyrosine kinase with a 60-kD molecular weight.It is a member of a 9-gene family named the Src family kinases (SFKs)”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [1]
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859 · cited 1×
“Focal adhesions are also disassembled during transformation, during which the integrity of these structures is disrupted, permitting increased motilit”
BackgroundCell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“This is followed by release of adhesions and retraction of the rear en”
BackgroundGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 1×
“Although not yet reported for c- SRC , it has been possible to transform human fibroblasts with oncogenes such as HRAS when they are combined with human telomerase reverse transcriptase and the SV40 large T antige”
BackgroundTransforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332 · cited 1×
“v- src was subsequently shown to encode a tyrosine-specific protein kinas”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 activation by v-Src has also been shown to contribute to other biological properties of cancer cells, including cell growth and survival, and tumour-cell immune evasio”
BackgroundFOCAL ADHESIONS, CONTRACTILITY, AND SIGNALING
Burridge, K., & Chrzanowska-Wodnicka, M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.463 · Cited by 1,942 · cited 1×
“Small adhesions can transmit stong forces for rapid movement and ultimately mature into larger focal adhesion”
BackgroundReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
llić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., et al. (1995) · Nature · doi:10.1038/377539a0 · Cited by 1,830
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D., & Birchmeier, W. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.173 · Cited by 1,551 · cited 1×
“Definitive studies in transgenic mice indicate that E-cadherin is an invasion suppresso”
BackgroundA causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424 · cited 1×
“and overexpression of E-cadherin can, in fact, counteract the acquisition of the invasive phenotyp”
Background
Cited by
Items 501–600 of 999
Focal adhesions control cleavage furrow shape and spindle tilt during mitosis
Taneja, N., Fenix, A. M., Rathbun, L. I., Millis, B. A., Tyska, M. J., Hehnly, H., & Burnette, D. T. (2016) · Scientific Reports · doi:10.1038/srep29846 · Cited by 32
“Epithelial cells form FAs on their basal domain and tight junctions and adherens junctions (i.e., cell-cell contacts) on their apical and lateral domains, respectively 12,13 .”
Callera, G. E., Antunes, T. T., He, Y., Montezano, A. C. I., Yogi, Á., Savoia, C., & Touyz, R. M. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07699 · Cited by 36
“Src family protein kinases are proto-oncogenes involved in cell morphology, motility, proliferation, and survival.(19,20) There are 11 members of the Src family in humans, of which c-Src, Fyn, and Yes are ubiquitously expressed.”
BackgroundSrc-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter
Wang, X., Wei, X., Yang, Y., Sun, Q., Zhan, J., Zhang, J., Tang, Y., Feng, L., Ding, L., Ye, Q., et al. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201708064 · Cited by 34
“Src, a nonreceptor tyrosine kinase, was confirmed as a critical component of a variety of pathways that regulate important cellular functions including proliferation, survival, adhesion, and migration (Yeatman, 2004).”
BackgroundLee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 41
“platelet-derived growth factor receptor, and other cell stressors such as reactive oxygen species.(70,71) Greater SRC activation in CRC tumors is associated with more advanced stage disease(72) and worse OS.”
BackgroundSalotti, J., Dias, M. H., Koga, M. M., & Armelin, H. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072582 · Cited by 35
“The Src family of protein tyrosine kinases is normally maintained in an inactive state, but they can be transiently activated by growth factors stimuli [39].”
BackgroundIa, K. K., Mills, R. D., Hossain, M. I., Chan, K., Jarasrassamee, B., Jorissen, R. N., & Cheng, H. (2010) · Growth Factors · doi:10.3109/08977194.2010.484424 · Cited by 35
Src binds cortactin through an SH2 domain cystine-mediated linkage
Evans, J. V., Ammer, A. G., Jett, J. E., Bolcato, C., Breaux, J. C., Martin, K. H., Culp, M. V., Gannett, P. M., & Weed, S. A. (2012) · Journal of Cell Science · doi:10.1242/jcs.121046 · Cited by 33
“Elimination of tyrosine 527 results in constitutive kinase activation and neoplastic transformation (Yeatman, 2004).”
BackgroundMethylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome
Fridley, B. L., Armasu, S. M., Cicek, M. S., Larson, M. C., Wang, C., Winham, S. J., Kalli, K. R., Koestler, D. C., Rider, D. N., Shridhar, V., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-21 · Cited by 34
“SRC is a target for many anticancer drugs [30].”
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death
Ratushny, V., Pathak, H. B., Beeharry, N., Tikhmyanova, N., Xiao, F., Li, T., Litwin, S., Connolly, D. C., Yen, T. J., Weiner, L. M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.314 · Cited by 33
Cherra, S. J., & Jin, Y. (2016) · Neuron · doi:10.1016/j.neuron.2015.12.024 · Cited by 32
Galectin-3 induced by hypoxia promotes cell migration in thyroid cancer cells
Zheng, J., Lu, W., Wang, C., Xing, Y., Chen, X., & Ai, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.21135 · Cited by 35
“The unchanged level of phosphorylated FAK supports the idea that FAK is not necessarily required for the increased motility that is induced by Src activation [50].”
BackgroundIn Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma
Ren, L., Li, Z., Wang, Y., Teng, Y., Sun, H., Xing, B., Yang, X. Y., Jiang, Y., & He, F. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000421 · Cited by 31
“Src can be deactivated by phosphorylation at Tyr530 and activated by autophosphorylation at Tyr419, and the N-terminal SH4 domain, which contains myristoylation site, is important for membrane localization (74, 81).”
BackgroundA Myristoyl Binding Site in the SH3 Domain Modulates c-Src Membrane Anchoring
Roux, A. L., Mohammad, I.-L., Mateos, B., Arbesú, M., Gairí, M., Khan, F. A., Teixeira, J. M. C., & Pons, M. (2018) · iScience · doi:10.1016/j.isci.2019.01.010 · Cited by 36
“…and therefore cell invasion and survival. c-Src deregulation is directly associated to poor prognosis in colorectal and breast cancer (Martin, 2001; Yeatman, 2004; Sen and Johnson, 2011; Sirvent et al., 2012). c-Src shares with the other SFKs a common domain arrangement formed by the…”
BackgroundHistorical retrospective of the SRC oncogene and new perspectives (Review)
Simatou, A., Simatos, G., Goulielmaki, M., Spandidos, D. A., Baliou, S., & Zoumpourlis, V. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2091 · Cited by 44
“In fact, its dysregulation could be characterized as an oncogenic signature and as a key factor for tumor progression (3,5,49).”
Wu, Y., Span, L. M., Nygren, P., Zhu, H., Moore, D. T., Cheng, H., Röder, H., DeGrado, W. F., & BENNETT, J. S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.648428 · Cited by 32
Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors
Ahmadi, M., Ahmadihosseini, Z., Allison, S. J., Begum, S., Rockley, K. L., Sadiq, M., Chintamaneni, S., Lokwani, R., Hughes, N., & Phillips, R. M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12438 · Cited by 37
“This is consistent with other studies showing that forced expression of HIF1 repressed Src signalling output by repressing transcription of PTP1B thereby conferring resistance to dasatinib (Suwaki et al., 2011).”
Pace, A., Tapia, J. A., Garcı́a, L. J., & Jensen, R. T. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.03.004 · Cited by 32
“The SFK members (c-Src, Fyn and Yes) are widely expressed in different tissues, whereas the others (including Lyn, Hck, Fgr, Blk, Yrk) have a more restrictive distribution [2].”
BackgroundOishi, J., Han, X., Kang, J., Asami, Y., Mori, T., Niidome, T., & Katayama, Y. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.08.032 · Cited by 32
Iterative Microarray and RNA Interference–Based Interrogation of the Src-Induced Invasive Phenotype
Irby, R., Malek, R. L., Bloom, G., Tsai, J., Letwin, N. E., Frank, B. C., Verratti, K. J., Yeatman, T. J., & Lee, N. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3609 · Cited by 33
“As an early member of a signal transduction cascade, Src exerts pleotropic effects on cell behavior through a number of pathways (1).”
BackgroundSelf-citationParadoxical activation of c-Src as a drug-resistant mechanism
Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31
Zeng, Z., Xu, L., Xu, J., Tian, X., Zhao, L., & Liao, X. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.145044 · Cited by 34
Rothschild, S. I., Каппелер, А., Ratschiller, D., Betticher, D. C., Tschan, M. P., Gugger, M., & Gautschi, O. P. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.06.018 · Cited by 31
“[4] Yeatman TJ.”
BackgroundInfluentialKomiya, Y., Onodera, Y., Kuroiwa, M., Nomimura, S., Kubo, Y., Nam, J.-M., Kajiwara, K., Nada, S., Oneyama, C., Sabe, H., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.59 · Cited by 29
SRC activates TAZ for intestinal tumorigenesis and regeneration
Byun, M. R., Hwang, J.-H., Kim, A. R., Kim, K. M., Park, J. I., Oh, H. T., Hwang, E. S., & Hong, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.003 · Cited by 36
Xu, J., Hua, X., Yang, R., Jin, H., Li, J., Zhu, J., Tian, Z., Huang, M., Jiang, G., Huang, H., et al. (2019) · Oncogenesis · doi:10.1038/s41389-019-0181-8 · Cited by 33
Song, S., Zhou, J., Li, Y., Liu, J., Li, J., & Shu, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-13223-z · Cited by 36
Lee, P., Lee, H.-J., Kakadiya, R., Sanjiv, K., Su, T.-L., & Lee, T. (2012) · Oncogene · doi:10.1038/onc.2012.133 · Cited by 31
Wadhawan, A., Smith, C. R., Nicholson, R. I., Barrett-Lee, P. J., & Hiscox, S. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.003 · Cited by 31
Hannon, R. A., Finkelman, R. D., Clack, G., Iacona, R. B., Rimmer, M., Gossiel, F., Baselga, J. M., & Eastell, R. (2012) · Bone · doi:10.1016/j.bone.2011.12.017 · Cited by 31
“The discrepancy between this and our findings in this study may be at least partially explained by the consideration that saracatinib is a SFK inhibitor rather than a specific Src inhibitor [1], and the large amount of functional redundancy in the Src kinase family [2].”
BackgroundResultAnomalous constitutive Src kinase activity promotes B lymphoma survival and growth
Ke, J., Chelvarajan, R. L., Sindhava, V. J., Robertson, D. A., Lekakis, L. J., JENNINGS, C. D., & Bondada, S. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-132 · Cited by 40
Frame, M. C., & Roskoski, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.07199-5 · Cited by 32
Lou, L., Yu, Z., Wang, Y., Wang, S., & Zhao, Y. (2018) · Cancer Science · doi:10.1111/cas.13572 · Cited by 31
Li, Y., Syed, L. U., Liu, J., Hua, D. H., & Li, J. (2012) · Analytica Chimica Acta · doi:10.1016/j.aca.2012.07.027 · Cited by 30
Ciccimaro, E., Hanks, S. K., & Blair, I. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.052464 · Cited by 30
“The Src family kinases comprise 11 structurally related, membrane-associated, nonreceptor protein tyrosine kinases including cellular-Src (c-Src), c-Yes, Fyn, Lyn, Hck, Blk, Brk, Fgr, Frk, Srm, and Yrk (Summy and Gallick, 2003; Yeatman, 2004; Meyn and Smithgall, 2008).”
BackgroundEnomoto, M., Vaughen, J. P., & Igaki, T. (2015) · Cancer Science · doi:10.1111/cas.12816 · Cited by 33
Zhou, Q., Jin, P., Liu, J., Wang, F., & Xi, S. (2018) · Metallomics · doi:10.1039/c8mt00131f · Cited by 29
Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis
Sirvent, A., Mevizou, R., Naim, D., Lafitte, M., & Roche, S. (2020) · Cancers · doi:10.3390/cancers12082014 · Cited by 35
“Src is also the prototype of SFK that includes eight members (Src, Fyn, Yes, Lck, Fgr, Hck, Blk and Lyn) of which three (Src, Fyn and Yes) are widely expressed [13,14].”
BackgroundKajiwara, K., Chen, P.-K., Abe, Y., Okuda, S., Kon, S., Adachi, J., Tomonaga, T., Fujita, Y., & Okada, M. (2022) · Current Biology · doi:10.1016/j.cub.2022.06.038 · Cited by 30
“Current Biology 32, 1–17, A This is an open access article und An oncogene product, Src, a membrane-anchored tyrosine kinase, plays a pivotal role in regulating various cellular functions including cell adhesion, migration, and invasion.(11) Src is overexpressed and/or activated in various malignant cancers, implying…”
Blažević, T., Schwaiberger, A. V., Schreiner, C. E., Schachner, D., Schaible, A. M., Grojer, C. S., Atanasov, A. G., Werz, O., Dirsch, V. M., & Heiß, E. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.489013 · Cited by 30
Kaimachnikov, N. P., & Kholodenko, B. Ν. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07117.x · Cited by 33
“prevents deactivation, but not phosphorylation of Sa1 by Csk [5, 7].”
BackgroundInfluentialKunte, D. P., Wali, R. K., Koetsier, J. L., Hart, J. A. L., Kostjukova, M. N., Kilimnik, A. Y., Pyatkin, I. G., Strelnikova, S. R., & Roy, H. K. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.030 · Cited by 30
Pathak, H. B., Zhou, Y., Sethi, G., Hirst, J. J., Schilder, R. J., Golemis, E. A., & Godwin, A. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144126 · Cited by 33
“They play key roles in regulating signal transduction from cell surface receptors [17–19] and therefore, modulate many cellular functions including tumor progression and metastasis in a variety of human tumors and have received a renewed interest as potential targets for therapy [20–23].”
BackgroundŚwierczyński, M., Szymaszkiewicz, A., Fichna, J., & Zielińska, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188460 · Cited by 33
Meyn, M. A., & Smithgall, T. E. (2009) · Science Signaling · doi:10.1126/scisignal.2000311 · Cited by 29
“In humans, there are 11 SFKs which regulate diverse cellular processes including proliferation, cellular adhesion, differentiation, and survival (5, 6).”
Prion protein and its role in signal transduction
Didonna, A. (2013) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-013-0085-0 · Cited by 29
“Fyn is a member of the Src protein family, a group of nine non-receptor tyrosine kinases that play a pivotal role in the regulation of different aspects of cell physiology [57].”
BackgroundProteomic, functional and motif‐based analysis of C‐terminal Src kinase‐interacting proteins
Yang, G., Li, Q., Ren, S., Lü, X., Fang, L., Zhou, W., Zhang, F., Xu, F., Zhang, Z., Zeng, R., et al. (2009) · PROTEOMICS · doi:10.1002/pmic.200800762 · Cited by 31
“Keywords: Cell biology / Protein complexes / Protein kinases / Protein–protein interaction / Shotgun proteomics / Src homology type 1 Introduction The Src family tyrosine kinases (SFKs), originally identified as proto-oncogene products, are non-receptor tyrosine kinases that play pivotal roles in cell proliferation, s…”
BackgroundEmerging strategies to overcome resistance to endocrine therapy for breast cancer
Ziauddin, M. F., Hua, D., & Tang, S.-C. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9504-6 · Cited by 36
“Src is a nonreceptor tyrosine kinase which is overexpressed or overactive in many cancers, including some breast cancers [44].”
BackgroundTsarouhas, V., Yao, L., & Samakovlis, C. (2014) · Journal of Cell Science · doi:10.1242/jcs.143016 · Cited by 32
“A standard model involves the de-phosphorylation of Y(527) of chicken c-src, which unlocks the autoinhibitory interaction and allows transauto-phosphorylation (Yeatman, 2004).”
BackgroundVergara, D., Simeone, P., Boccio, P. D., Toto, C., Pieragostino, D., Tinelli, A., Acierno, R., Alberti, S., Salzet, M., Giannelli, G., et al. (2012) · Molecular BioSystems · doi:10.1039/c2mb25401h · Cited by 33
Ojemuyiwa, M. A., Madan, R. A., & Dahut, W. L. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.969239 · Cited by 30
“They are the largest family of no receptor protein tyrosine kinases and are responsible for signal transduction during many cellular activities, including, adhesion, differentiation and migration [52].”
BackgroundCozzi, M., Giorgi, F. D., Marcelli, E., Pentimalli, F., Forte, I. M., Schenone, S., D’Urso, V., Falco, G. D., Botta, M., Giordano, A., et al. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19519 · Cited by 37
“Hyperactivation of the non-receptor tyrosine kinase SRC has been demonstrated in several human cancers, and this kinase is considered an important molecular target in cancer therapy because of its central role in regulating key processes in tumor development, such as proliferation, apoptosis, angiogenesis and invasion…”
BackgroundUnderstanding the biology of urothelial cancer metastasis
Kobayashi, T. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.09.005 · Cited by 32
“c-Src has been recognized to promote metastasis of cancers by modifying focal adhesion and cellecell junction mediated by integrins and cadherins [92,93].”
BackgroundNoronha, G., Barrett, K., Cao, J., Dneprovskaia, E., Fine, R., Gong, X., Gritzen, C., Hood, J. D., Kang, X., Klebansky, B., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.035 · Cited by 29
Src-family tyrosine kinases as therapeutic targets in advanced cancer
Gelman, I. H. (2011) · Frontiers in Bioscience · doi:10.2741/e287 · Cited by 28
Chen, P.-H., Peng, C.-Y., Pai, H.-C., Teng, C.-M., Chen, C.-C., & Yang, C.-R. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.06.004 · Cited by 28
“In addition, its ability to promote tumor cell invasion can lead to the development of tumor metastasis [11].”
BackgroundCyr61 as mediator of Src signaling in triple negative breast cancer cells
Sánchez-Bailón, M. P., Calcabrini, A., Mayoral-Varo, V., Molinari, A., Wagner, K., Pérez‐Losada, J., Ciordia, S., Albar, J. P., & Martín-Pérez, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3760 · Cited by 32
“Consequently, SFKs control signal transduction pathways that regulate cell division, motility, adhesion, migration, angiogenesis, survival, and differentiation [1, 10–12].”
BackgroundSu, C.-M., Su, Y., Chiu, C., Chang, Y.-W., Hong, C., Yu, Y.-H., Ho, Y., Wu, C., Yen, C.-S., & Su, J.-L. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4009-7 · Cited by 28
“CTTN has been reported as a downstream target of Src and activation of Src involves in VEGFR-induced cell mobility.(16) To study the role of Src in VEGF-C-mediated CTTN upregulation and cell migration/invasion, we knocked down Src in TE-1 cells and followed by rhVEGFC treatment to examine cell migration/invasive abili…”
MethodPathways of metastasis suppression in bladder cancer
Said, N. A., & Theodorescu, D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9197-4 · Cited by 29
“Correlative and experimental evidences demonstrated that the expression and activity of c-Src was positively correlated with tumor grade and stage in several cancers [28, 30, 31].”
BackgroundInfluentialLarsen, S. L., Lænkholm, A., Duun‐Henriksen, A. K., Bak, M., Lykkesfeldt, A. E., & Kirkegaard, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118346 · Cited by 31
“Inactive Src is located in the cytoplasm and at perinuclear sites, whereas activated Src is localized at the plasma membrane [9].”
BackgroundKirkegaard, T., Hansen, S. K., Larsen, S. L., Reiter, B. E., Sørensen, B. S., & Lykkesfeldt, A. E. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.014 · Cited by 33
“c-Src belongs to the family of non-receptor tyrosine kinases consisting of 9 members [42].”
Veracini, L., Grall, D., Schaub, S., Divonne, S. B.-D. L. F., Étienne-Grimaldi, M.-C., Milano, G. A., Bozec, A., Babin, E., Sudaka, A., Thariat, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3071 · Cited by 31
“Autophosphorylation at tyrosine 419 (Y419, Y416 in chicken) is required for full activation of Src [5] and the phosphorylation status at this site is commonly used to monitor the active kinase.”
BackgroundZhao, R., Wu, Y., WANG, T., Zhang, Y., Kong, D., Zhang, L., Li, X., Wang, G., Jin, Y., Jin, X., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3706 · Cited by 28
“Src is characterized as an oncogene, and the overexpression and/or elevated activity of Src appears to be involved in the progression of various tumor types, including HCC (11,12).”
Gao, Z., Zhao, G., Lv, Y., Peng, D.-B., Tang, X., Song, H., & Guo, Q. (2018) · Oncology Reports · doi:10.3892/or.2018.6827 · Cited by 34
c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer
Hunter, C. A., Koç, H., & Koc, E. C. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109651 · Cited by 31
Fujisaka, Y., Onozawa, Y., Kurata, T., Yasui, H., Goto, I., Yamazaki, K., Machida, N., Watanabe, J., Shimada, H., Shi, X., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9809-7 · Cited by 34
“Src is a non-receptor tyrosine kinase involved in signal transduction pathways that regulate processes of survival, proliferation, adhesion, and migration [1, 2].”
BackgroundYuan, Z., McCauley, R. B., Chen-Scarabelli, C. A., Abounit, K., Stephanou, A., Barry, S. P., Knight, R. A., Saravolatz, S., Saravolatz, L. D., Ulgen, B. O., et al. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.013 · Cited by 28
“The overexpression and activation of Src family kinases has been linked to a variety of human malignancies (Yeatman, 2004).”
BackgroundHeijink, D. M., Fehrmann, R. S. N., de Vries, E. G. E., Koornstra, J. J., Oosterhuis, D., van der Zee, A. G. J., KLEIBEUKER, J. H., & de Jong, S. (2011) · Oncogene · doi:10.1038/onc.2010.578 · Cited by 28
“Src family kinases are involved in many tumorigenic events, including proliferation, survival, angiogenesis, adhesion, invasion and metastasis (”
BackgroundSimultaneous deactivation of FAK and Src improves the pathology of hypertrophic scar
Su, L., Li, X., Wu, X., Hui, B., Han, S., Gao, J., Li, Y., Shi, J., Zhu, H., Zhao, B., et al. (2016) · Scientific Reports · doi:10.1038/srep26023 · Cited by 30
Tyr42 phosphorylation of RhoA GTPase promotes tumorigenesis through nuclear factor (NF)-κB
Kim, J.-G., Choi, K.-C., Hong, C.-W., Park, H.-S., Choi, E.-K., Kim, Y.-S., & Park, J.-B. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.013 · Cited by 28
“Although Src is an important oncogenic protein, the mechanism of tumorigenesis by Src was not completely elucidated [46].”
BackgroundBaird, K., Glod, J. W., Steinberg, S. M., Reinke, D. K., Pressey, J. G., Mascarenhas, L., Federman, N. C., Marina, N. M., Chawla, S. P., Lagmay, J., et al. (2020) · Sarcoma · doi:10.1155/2020/7935475 · Cited by 30
“Subsequently, increased activity or expression of Src was found in many common solid tumors, including the lung and several gastrointestinal tumors involving the esophagus, stomach, liver, pancreas, and colon [8].”
Activation of Src and transformation by an RPTPα splice mutant found in human tumours
Huang, J., Yao, L., Xu, R., Wu, H., Wang, M., White, B. S., Shalloway, D., & Zheng, X. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.212 · Cited by 27
“Src protein tyrosine kinase specific activity is increased without mutation in many human cancers, suggesting that aberrant upstream regulation is involved (Yeatman, 2004; Wheeler et al, 2009).”
BackgroundCeccherini, E., Indovina, P., Zamperini, C., Dreassi, E., Casini, N., Cutaia, O., Forte, I. M., Pentimalli, F., Esposito, L., Polito, M. S., et al. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25042 · Cited by 27
Regional Treatment Strategies for In-Transit Melanoma Metastasis
Turley, R. S., Raymond, A. K., & Tyler, D. S. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.09.008 · Cited by 27
“Src kinase overexpression leads to increased cellular proliferation and decreased adhesion.(130) Src signals through its downstream intermediaries, called signal transducers and activa-”
Gilani, R. A., Phadke, S., Bao, L., Lachacz, E. J., Dziubinski, M. L., Brandvold, K. R., Steffey, M. E., Kwarcinski, F. E., Graveel, C. R., Kidwell, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2158 · Cited by 30
“UM-164 alters the cellular localization of c-Src Inhibiting kinases via an inactive conformation can alter noncatalytic functions of the protein and/or its cellular localization (15, 42).”
BackgroundRetractedEnomoto, M., Takemoto, D., & Igaki, T. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.07.002 · Cited by 30
Haraoka, Y., Akieda, Y., Nagai, Y., Mogi, C., & Ishitani, T. (2022) · Nature Communications · doi:10.1038/s41467-022-29061-6 · Cited by 28
“larvae(n): (5) (7) cells(n): (27) (36) Ras cell”
Src activates Abl to augment Robo1 expression in order to promote tumor cell migration
Khusial, P. R., Vadla, B., Krishnan, H., Ramlall, T. F., Shen, Y., Ichikawa, H., Geng, J.-G., & Goldberg, G. S. (2010) · Oncotarget · doi:10.18632/oncotarget.126 · Cited by 31
“Src and Abl are nonreceptor tyrosine kinases, that can inturn phosphorylate a variety of substrates, including Cas, Crk, and paxillin, to initiate cell spreading and migration [4-6].”
BackgroundStrickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27
“When src is activated on the plasma membrane inner surface, it interacts with several proteins, including E-cadherin, Focal Adhesion Kinase (FAK), integrins, and STAT-3 [39].”
Su, T., Pan, S., Luo, Q., & Zhang, Z. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.02.024 · Cited by 27
Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Huang, Z. Q., Saluja, A. K., Dudeja, V., Vickers, S. M., & Buchsbaum, D. J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796957427 · Cited by 46
Stegeman, H., Kaanders, J. H. A. M., Verheijen, M. M., Peeters, W. J. M., Wheeler, D. L., Iida, M., Grenman, R. A., van der Kogel, A. J., Span, P. N., & Bussink, J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-133 · Cited by 29
“SFKs have been shown to be involved in pathways that control cell division and survival [22,23] and Src has been implicated in AKT activation after radiotherapy [24].”
BackgroundToni, E. N. D., Kuntzen, C., Gerbes, A. L., Thasler, W. E., Sonuc, N., Mucha, S. R., Čamaj, P., Bruns, C. J., Göke, B., & Eichhorst, S. T. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.010 · Cited by 30
Welman, A., Cawthome, C., Ponce-Perez, L., Barraclough, J., Danson, S., Murray, S., Cummings, J., Allen, T. D., & Dive, C. (2006) · Neoplasia · doi:10.1593/neo.06475 · Cited by 26
“vival, differentiation, adhesion, and motility [1,2].”
BackgroundMethodHuang, H., Ma, J., Shi, J., Meng, L., Jiang, H., Ding, J., & Liu, H. S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.032 · Cited by 26
An effective cell-penetrating antibody delivery platform
Herrmann, A., Nagao, T., Zhang, C., Lahtz, C., Li, Y., Yue, C., Mülfarth, R. I., & Yu, H. (2019) · JCI Insight · doi:10.1172/jci.insight.127474 · Cited by 29
“Although v-Src is truncated at 526aa, Src tyrosine kinase has been found to be overexpressed and highly activated at Y418 in numerous human cancers (34, 35).”
BackgroundLabel-free spectroscopic characterization of exosomes reveals cancer cell differentiation
Romanò, S., Giacinto, F. D., Primiano, A., Gervasoni, J., Mazzini, A., Papi, M., Urbani, A., Serafino, A., Spirito, M. D., Krasnowska, E. K., et al. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339359 · Cited by 31
Cheng, E., Whitsett, T. G., Tran, N. L., & Winkles, J. A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0411 · Cited by 31
“SFKs, via their effects on gene expression, cytoskeletal reorganization, and cellular adhesion, are major intracellular mediators of tumor cell migration and invasion (24, 25, 46, 47).”
BackgroundHaura, E. B. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31601-4 · Cited by 32
Dong, S., Khoo, A., Wei, J., Bowser, R. K., Weathington, N. M., Xiao, S., Zhang, L., Ma, H., Zhao, Y., & Zhao, J. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00132.2014 · Cited by 27
“Y416 phosphorylation activates c-Src, while Y530 phosphorylation inhibits c-Src kinase activity (9, 16, 55).”
BackgroundProteomic identification of ZO-1/2 as a novel scaffold for Src/Csk regulatory circuit
Saito, K., Enya, K., Oneyama, C., Hikita, T., & Okada, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.12.055 · Cited by 26
Bacarizo, J., Martínez‐Rodríguez, S., Martin-Garcia, J. M., Andújar‐Sánchez, M., Ortiz‐Salmerón, E., Neira, J. L., & Cámara-Artigas, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113224 · Cited by 26
“This protein has been implicated in the development, growth, progression and metastasis of several cancers [1].”
BackgroundCasini, N., Forte, I. M., Mastrogiovanni, G., Pentimalli, F., Angelucci, A., Festuccia, C., Tomei, V., Ceccherini, E., Marzo, D. D., Schenone, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3043 · Cited by 28
“Indeed, increased SRC kinase activity is associated with the metastatic potential of many tumor types and SRC has an important role in regulating focal adhesion and adherent junctions, which are the principal subcellular structures involved in cell adhesion, motility and invasion [6].”
InfluentialZheng, J. J., Li, H., Xu, D., & Zhu, H. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2218 · Cited by 28
“21 Furthermore, it was observed that FYN is positively associated with cellular motility, proliferation, and apoptosis in human TC.”
Ridolfi, E., Matteucci, E., Maroni, P., & Desiderio, M. A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604726 · Cited by 26
“c-Src is a critical component of the pathways regulating proliferation, survival and metastasis (through effects on adhesion, invasion and motility), and is one of the Met-signal transducers involved in the regulation of NF-kB activity (Huang et al, 2003a; Yeatman, 2004; Mazzone and Comoglio, 2006).”
BackgroundThe discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors
Robinett, R. G., Freemerman, A. J., Skinner, M. A., Shewchuk, L. M., & Lackey, K. E. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.104 · Cited by 26
Morrow, C. J., Ghattas, M. A., Smith, C., Bönisch, H., Bryce, R. A., Hickinson, D. M., Green, T. P., & Dive, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0694 · Cited by 28
“org loaded from A major role of c-Src activity in cancer is promotion of migration and invasion leading to a more aggressive and metastatic cancer phenotype (9).”
BackgroundPlanas-Silva, M. D., & Hamilton, K. N. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0398-z · Cited by 26
“For example, several compounds against the non-receptor tyrosine kinase c-Src are currently in clinical trials [11, 12, 38].”
Trihydrophobin 1 Phosphorylation by c-Src Regulates MAPK/ERK Signaling and Cell Migration
Wu, W., Sun, Z., Wu, J., Peng, X., Gan, H., Zhang, C., Ji, L., Xie, J., Zhu, H., Ren, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029920 · Cited by 25
“Activated EGFR family receptor tyrosine kinases (RTKs) recruit and activate c-Src, and c-Src in turn further activates RTKs, stimulating MAPK/ERK signaling [4,34]. c-Src is also activated by ligand-bound estrogen receptor (ER), which stimulates rapid, transient recruitment of c-Src and activates MAPK signaling [35].”
BackgroundInfluentialSrc Points the Way to Biomarkers and Chemotherapeutic Targets
Krishnan, H., Miller, W. T., & Goldberg, G. S. (2012) · Genes & Cancer · doi:10.1177/1947601912458583 · Cited by 26
Toxicogenetic and antiproliferative effects of chrysin in urinary bladder cancer cells
Lima, A. P. B., Almeida, T. C., Barros, T. M. B., Rocha, L. C. M., Garcia, C. C. M., & da Silva, G. N. (2020) · Mutagenesis · doi:10.1093/mutage/geaa021 · Cited by 28
Metadata
- Authors
- Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Yeatman, Timothy J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 470-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2036988959
- Cited by
- 1,113
- References
- 115
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 20 · 2023: 43 · 2022: 43 · 2021: 46 · 2020: 44 · 2019: 39 · 2018: 49 · 2017: 44 · 2016: 69 · 2015: 56 · 2014: 72 · 2013: 79 · 2012: 73
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, non-receptor tyrosine kinase, cancer, metastasis, cell invasion, cell motility, cell proliferation, anticancer agents, tumor progression
- MeSH terms
- Antineoplastic Agents, Cell Division, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Phenotype, Gene Expression Regulation, Neoplastic, Genes, src, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.